Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease

Documenti analoghi

• Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers
  di: Xiaoxu Wang, et al.
  Pubblicazione: (2024)
• Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions
  di: Sergei Noskov, et al.
  Pubblicazione: (2024)
• Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor
  di: Ryuzo Hanada, et al.
  Pubblicazione: (2025)
• Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers
  di: Gang Chen, et al.
  Pubblicazione: (2025)
• Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers
  di: Shengling Hu, et al.
  Pubblicazione: (2024)